
What is claimed is:

1. A compound having a structure of Formula (I):



(I),

or a pharmaceutically acceptable salt of the compound,

wherein:

A is a 6-8 membered heterocycle comprising 1 or 2 ring nitrogen atoms and optionally substituted with 1 to 3 substituents independently selected from halogen, OH, and C_{1-3}alkyl;

Y is a bond, O, S, CH_2, CHF, CF_2, or C(OH)H;

m is 1 or 2;

n is 1 or 2;

p is 1 or 2;

R^1 is H, halogen, CN, OH, $-N(R^6)(R^7)$, C_{1-6}alkyl, C_{2-6}heteroalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, $-[O]_{0-1}$-C_{3-6}cycloalkyl, $-[O]_{0-1}$-C_{6-10}aryl, $-[O]_{0-1}$-4-8 membered heterocycle or $-[O]_{0-1}$-5-10 membered heteroaryl, wherein the heterocycle and heteroaryl each comprises 1, 2, or 3 ring heteroatoms selected from N, O, and S, and when R^1 is C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, $-[O]_{0-1}$-C_{3-6}cycloalkyl, $-[O]_{0-1}$-C_{6-10}aryl, $-[O]_{0-1}$-4-8 membered heterocycle,$-[O]_{0-1}$-5-10 membered heteroaryl, -NH-C_{3-6}cycloalkyl, -NH-C_{6-10}aryl, -NH-4-8 membered heterocycle, -NH-5-10 membered heteroaryl, -N(C_{1-6}alkyl)-C_{3-6}cycloalkyl, -N(C_{1-6}alkyl)-C_{6-10}aryl, -N(C_{1-6}alkyl)-4-8 membered heterocycle, or -N(C_{1-6}alkyl)-5-10 membered heteroaryl, R^1 is optionally substituted with 1, 2, or 3 substituents independently selected from halogen, CN, OH, =O, SO_2, and C_{1-3}alkyl,

R^2 is H, halogen, CN, OH, $-N(R^6)(R^7)$, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6}alkoxy, C_{1-6}haloalkoxy, C_{2-6}heteroalkyl, C_{3-6}cycloalkyl, or 4-8 membered heterocycle comprising 1, 2, or 3 ring heteroatoms selected from N, O, and S;

R^3 is halogen, CN, OH, $-N(R^6)(R^7)$, C_{1-6}alkyl, C_{2-6}heteroalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, $-[O]_{0-1}$-C_{3-6}cycloalkyl, $-[O]_{0-1}$-C_{6-10}aryl, $-[O]_{0-1}$-4-8 membered heterocycle, or $-[O]_{0-1}$-5-10 membered heteroaryl, -NH-C_{3-6}cycloalkyl, -NH-C_{6-10}aryl, -NH-4-8 membered heterocycle, -NH-5-10 membered heteroaryl, -N(C_{1-6}alkyl)-C_{3-6}cycloalkyl, -N(C_{1-6}alkyl)-C_{6-10}aryl, -N(C_{1-6}alkyl)-4-8 membered heterocycle, or -N(C_{1-6}alkyl)-5-10 membered heteroaryl, wherein the heterocycle and heteroaryl each comprises 1, 2, or 3 ring heteroatoms selected from N, O, and S, and the C_{3-6}cycloalkyl, -C_{6-10}aryl, 4-8 membered heterocycle, or 5-10 membered heteroaryl is substituted with 0, 1, 2, or 3 R^{3a} substituents;

each R^{3a} is independently selected from halogen, CN, OH, =O, =N(C_{1-3}alkly), SO_2, C_{1-6}alkyl, C_{2-10}alkene, C_{1-6}hydroxyalkyl , C_{1-6}haloalkyl, C_{1-6}alkoxy, C_{1-6}haloalkoxy, C_{1-6}alkylene-O-C_{1-6}alkyl, C_{0-6}alkylene-NH_2, C_{0-6}alkylene-NH(C_{1-6}alkyl), C_{0-6}alkylene-N(C_{1-6}alkyl)$_2$, -S-C_{1-6}alkyl, C_{0-6}alkylene-SO_2C_{1-6}alkyl, C_{0-6}alkylene-C(O)NH_2, C_{0-6}alkylene-C(O)NH(C_{1-6}alkyl), C_{0-6}alkylene-C(O)N(C_{1-6}alkyl)$_2$, C_{0-6}alkylene-NHC(O)C_{1-6}alkyl, C_{0-6}alkylene-

COOH, C_{0-6}alkylene-C_{3-6}cycloalkyl, C_{1-6}alkylene-O-C_{1-6}alklyeneSi(C_{1-3}alkyl)$_3$, and C_{0-6}alkylene-3-6 membered heterocycle comprising 1, 2, or 3 heteroatoms selected from N, O, and S;



R^4 is H, halogen, CN, or OH;

R^5 is -CO_2-Z, or a bioisostere thereof;


each R^6 and R^7 is independently H, C_{1-6}alkyl, C(O)-C_{1-6}alkyl, spiro or bicyclic C_{8-14}cycloalkyl, 8-14 membered heterocycle comprising 1, 2, or 3 ring heteroatoms selected from N, O, and S, and when R^6 or R^7 is other than H, it can be optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, CN, =O, SO_2, OH, C_{0-6}alkylene-NH_2, C_{0-6}alkylene-NH(C_{1-6}alkyl), C_{0-6}alkylene-N(C_{1-6}alkyl)$_2$, C_{0-6}alkylene-SO_2C_{1-6}alkyl, C_{1-6}alkyl and C_{1-6}alkoxy, or

R^6 and R^7, together with the nitrogen to which they are attached, form a 4-10 membered heterocycle comprising 0-2 additional ring heteroatoms independently selected from N, O, and S; and

Z is C_{1-7}alkyl, C_{1-7}haloalkyl, C_{3-6}cycloalkyl, or C_{2-6}alkyne, and Z is optionally substituted with C_{1-6}alkoxy or C_{3-6}cycloalkyl;


with the proviso that when R^1, R^2, and R^4 are each H, Y is CH_2, m, n, and p are each 1, A is , and R^3 is trifluoroethoxy, trifluoromethoxy, difluoromethoxy, methoxy, or , then R^5 is not $CO_2CH_2CH_3$.

2. The compound or salt of claim 1, having a structure of Formula (Ib):




(Ib).

3. The compound or salt of claim 2, having a structure of Formula (Id):



(Id).

4. The compound or salt of claim 1, having a structure of Formula (Ie), or a pharmaceutically acceptable salt thereof:










































(Ie).

5. The compound or salt of claim 1, wherein R^5 is $CO_2CH_2CH_3$.


6. The compound or salt of claim 1, wherein R^1 is H or halogen.

7. The compound or salt of claim 1, wherein at least one of R^1, R^2, R^3, and R^4 is halogen.

8. The compound or salt of claim 1, wherein R^3 is , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and is optionally substituted with 1, 2, or 3 R^{3a}.

9. The compound or salt of claim 1, wherein R^3 is unsubstituted.

10. The compound or salt of claim 1, having a structure of Formula (If), or a pharmaceutically acceptable salt thereof:



(If),

wherein

R^1 is halogen;

R^3 is -$[O]_{0-1}$-C_{3-6}cycloalkyl, -$[O]_{0-1}$-C_{6-10}aryl, -$[O]_{0-1}$-4-8 membered heterocycle, or -$[O]_{0-1}$-5-10 membered heteroaryl, wherein the heterocycle and heteroaryl each comprises 1, 2, or 3 ring heteroatoms selected from N, O, and S, and R^3 is substituted with 0, 1, 2, or 3 R^{3a} substituents;

R^5 is CO_2Z. or a bioisostere thereof; and

Z is C_{1-7}alkyl, C_{1-7}haloalkyl, C_{3-6}cycloalkyl, or C_{2-6}alkyne, and is optionally substituted with C_{1-6}alkoxy or C_{3-6}cycloalkyl.


11. The compound or salt of claim 10, wherein R^1 is Cl or F.

12. The compound or salt of claim 10, wherein R^3 is 5-6-membered heterocycle comprising 1 ring heteroatom selected from S and O, or 5-6-membered heteroaryl comprising 2 or 3 ring heteroatoms independently selected from N and S, and R^3 is substituted with 0, 1 or 2 R^{3a} substituents independently selected from halogen, CN, OH, and C_{1-6}alkyl.

13. The compound or salt of claim 10, wherein R^5 is CO_2C_{1-7}alkyl.

14. The compound or salt of claim 13, wherein R^5 is CO_2Et.


15. The compound of claim 1, wherein the compound has the structure:



,


or a pharmaceutically acceptable salt thereof.

16. The compound of claim 15, wherein the compound has the structure:



.

17. The compound of claim 15, wherein the compound is a pharmaceutically acceptable salt of the compound having the structure:



.